Raphael Pharmaceutical (RAPH) Profit After Tax (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Profit After Tax came in at -$223000.0 in Q2 2026, up 30.75% year-over-year from -$170560.6 in Q2 2025, and up 30.75% quarter-over-quarter from -$322000.0 in Q2 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Profit After Tax (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Profit After Tax across 7 years of filings, most recently posting -$223000.0 for Q2 2026.
- In Q2 2026, Profit After Tax rose 30.75% year-over-year to -$223000.0; the TTM figure through Jun 2026 stood at -$1.4 million (up 7.0% YoY), while the FY2025 annual figure was -$1.3 million, up 15.8% from the prior year.
- Profit After Tax came in at -$223000.0 for Q2 2026 at Raphael Pharmaceutical, up from -$322000.0 in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $122000.0 in Q4 2023 to a low of -$1.4 million in Q3 2022.
- Average Profit After Tax over 5 years is -$475666.7, with a median of -$395000.0 recorded in 2024.
- Year-over-year, Profit After Tax jumped 111.06% in 2023 and tumbled 423.77% in 2024.
- Over 5 years, Profit After Tax stood at -$1.1 million in 2022, then jumped by 111.06% to $122000.0 in 2023, then plunged by 423.77% to -$395000.0 in 2024, then climbed by 18.48% to -$322000.0 in 2025, then jumped by 30.75% to -$223000.0 in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$223000.0 in Q2 2026, -$322000.0 in Q2 2025, and -$429000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | -223,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -223,000.00 |
| Jun 30, 2025 | -322,000.00 |
| Mar 31, 2025 | -429,000.00 |
| Dec 31, 2024 | -395,000.00 |
| Sep 30, 2024 | -326,000.00 |
| Jun 30, 2024 | -248,000.00 |
| Mar 31, 2024 | -550,000.00 |
| Dec 31, 2023 | 122,000.00 |
| Sep 30, 2023 | -725,000.00 |
| Jun 30, 2023 | -417,000.00 |
| Mar 31, 2023 | -264,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Jun 30, 2022 | -627,000.00 |
| Mar 31, 2022 | -185,000.00 |
| Dec 31, 2021 | -567,000.00 |
| Sep 30, 2021 | -416,000.00 |
| Jun 30, 2021 | -387,000.00 |
| Mar 31, 2021 | -255,000.00 |
| Dec 31, 2020 | -230,000.00 |